Medroxyprogesterone acetate pharmacology
Pro Research Analysisby 
Searched over 200M research papers
Medroxyprogesterone Acetate Pharmacologic Category and Chemical Properties
Medroxyprogesterone acetate (MPA) is classified as a progestogen or sex hormone. It is a synthetic derivative of progesterone and is active when administered orally or by injection. MPA is a white to off-white, odorless crystalline powder, stable in air, and has specific solubility characteristics: it is freely soluble in chloroform, soluble in acetone and dioxane, sparingly soluble in alcohol and methanol, slightly soluble in ether, and insoluble in water. Its chemical structure is based on pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-.
Medroxyprogesterone Acetate Pharmacokinetics and Drug Interactions
Depot medroxyprogesterone acetate (DMPA) is widely used as an injectable contraceptive. MPA is metabolized by the cytochrome P450 enzyme CYP3A4, making it susceptible to drug–drug interactions. When co-administered with certain antiretroviral drugs (like efavirenz) or antituberculosis treatments (such as rifampicin and isoniazid), the clearance of MPA increases, leading to lower drug concentrations and a higher risk of contraceptive failure. Conversely, drugs like lopinavir/ritonavir and nelfinavir decrease MPA clearance, but lopinavir/ritonavir also shortens its half-life. Adjusting the dosing interval to every 8–10 weeks, instead of the standard 12 weeks, can help maintain therapeutic MPA levels and reduce the risk of contraceptive failure in women taking these interacting medications.
Medroxyprogesterone Acetate Effects on Genital Mucosal Barrier and Infection Susceptibility
MPA use has been shown to reduce the expression of cell–cell adhesion molecules (CCAMs) such as desmoglein-1 and desmocollin-1 in genital tissues, leading to increased mucosal permeability. This effect is dose-dependent and has been linked to higher susceptibility to genital infections, including herpes simplex virus type 2 (HSV-2). Animal studies demonstrate that serum MPA concentrations similar to those seen in women using DMPA can significantly impair genital mucosal barrier function and increase infection risk.
Medroxyprogesterone Acetate and Immune System Suppression
MPA suppresses both innate and adaptive immune responses. It inhibits the production of key cytokines and chemokines involved in immune defense, such as interferon-gamma (IFN-γ), IL-2, IL-4, IL-6, IL-12, TNF-α, and others. MPA also reduces the ability of immune cells to respond to pathogens and increases HIV-1 replication in activated immune cells. Women using DMPA have been found to have lower levels of IFN-α in plasma and genital secretions, suggesting a reduction in host resistance to infections.
Medroxyprogesterone Acetate and Neuroprotective Effects
Unlike natural progesterone, MPA does not increase the expression of brain-derived neurotrophic factor (BDNF), which is important for neuroprotection. While progesterone can elevate BDNF levels and provide neuroprotective benefits, MPA lacks this effect, indicating that not all progestins have the same impact on brain health. This difference may influence the effectiveness of hormone therapy formulations for menopausal symptoms and disease risk reduction.
Conclusion
Medroxyprogesterone acetate is a synthetic progestogen with distinct pharmacologic, pharmacokinetic, and immunologic properties. Its metabolism is influenced by drug–drug interactions, and it can impact mucosal barrier function and immune responses, potentially increasing susceptibility to infections. Additionally, MPA differs from natural progesterone in its effects on neuroprotection, highlighting the importance of progestin selection in clinical use.
Sources and full results
Most relevant research papers on this topic